Ovarian Cancer Clinical Trials in Cleveland

Showing 41-60 of 120 trials

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

NCT05563272

A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.

Cervical CancerColorectal CancerEsophageal Cancer+16 more

Telix Pharmaceuticals (Innovations) Pty Ltd11 participantsStarted Jun 2023

Los Angeles, California, United States • Miami, Florida, United States • Boston, Massachusetts, United States +7 more locations

ACTIVE_NOT_RECRUITINGPHASE3< 1 mile

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT04498117

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.

Carcinoma, Ovarian EpithelialOvarian NeoplasmsOvarian Cancer+7 more

CanariaBio Inc.615 participantsStarted Aug 2020

Phoenix, Arizona, United States • Tucson, Arizona, United States • Concord, California, United States +145 more locations

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Ovarian Cancer Trials in Other Cities

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

FPA150 in Patients With Advanced Solid Tumors

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

A Study of ZN-c3 in Patients With Ovarian Cancer

Living WELL: A Web-Based Program for Ovarian Cancer Survivors

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Other Conditions in Cleveland